Sanofi

SAN

FR0000120578

Pharmaceuticals

Real-time Euronext Paris Other stock markets 06:21:08 2024-05-09 am EDT			5-day change	1st Jan Change
92.26 ^EUR	-0.88%		+0.39%	+2.79%

May. 07	Sanofi Close to Choosing BNP, BofA for Consumer Health Spinoff Deal	MT
May. 06	Bank of America, BNP Set to Win Lead Roles on Sanofi's Consumer-Healthcare Spin Off	MT

SANOFI : Goldman Sachs reiterates its Buy rating

May 03, 2021 at 05:21 pm EDT

Keyur Parekh from Goldman Sachs retains his positive opinion on the stock with a Buy rating. The target price is increased from EUR 101 to EUR 105.

Latest news about Sanofi

Sanofi Close to Choosing BNP, BofA for Consumer Health Spinoff Deal	May. 06	MT
Bank of America, BNP Set to Win Lead Roles on Sanofi's Consumer-Healthcare Spin Off	May. 06	MT
Sector Update: Financial Stocks Higher Monday Afternoon	May. 06	MT
Bank of America, BNP Set to Win Lead Roles on Sanofi's Consumer-Healthcare Spin Off	May. 06	MT
Bank of America, BNP Set to Win Lead Roles on Sanofi's $20 Billion Consumer Healthcare Spin Off, Bloomberg Reports	May. 06	MT
SANOFI : Buy rating from UBS	May. 06	ZD
GSK plc : Back on track	May. 03
European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading	May. 02	MT
Sanofi: new positive data for Beyfortus	May. 02	CF
Sanofi Announces Board and Committee Appointments	Apr. 30	CI
Sanofi Approves Ordinary Annual Dividend for the Fiscal Year 2023, Payable on May 15, 2024	Apr. 30	CI
European Equities Traded in the US as American Depositary Receipts Decline	Apr. 30	MT
SANOFI : Jefferies reiterates its recommendation on the stock	Apr. 29	CF
SANOFI : Deutsche Bank gives a Sell rating	Apr. 29	ZD
SANOFI : JP Morgan remains Neutral	Apr. 29	ZD
Sanofi to present advances at ATS in San Diego	Apr. 26	CF
Health Care Drops Amid Mixed Earnings -- Health Care Roundup	Apr. 25	DJ
SANOFI : DZ Bank reaffirms its Neutral rating	Apr. 25	ZD
European Equities Close Mostly Lower in Thursday Trading; BHP Bids Nearly $39 Billion to Acquire Anglo American	Apr. 25	MT
CAC40: manages to reduce losses at the end of the session	Apr. 25	CF
Global markets live: Ford, Dow, American Airlines, Comcast, Apple, IBM, Cisco...	Apr. 25
CAC40: losses trimmed, rates remain at their zenith	Apr. 25	CF
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	Apr. 25	MT
Sanofi Reaffirms Earnings Guidance for the Year 2024	Apr. 25	CI
CAC40: U.S. growth and inflation hold up, Nasdaq -2%.	Apr. 25	CF

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).

Sector

Pharmaceuticals

Calendar

2024-05-12 - Ex-dividend day for final dividend

Related indices

CAC 40 , EURO STOXX 50 , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

SANOFI : Sanofi’s healthy Q1 performance hailed by markets

April 25, 2024 at 07:58 am EDT

Sanofi Sees Trend for Years of Steady Growth: CFO

February 03, 2023 at 03:56 pm EST

More Strategies

Ratings for Sanofi

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

93.08 EUR

Average target price

108.1 EUR

Spread / Average Target

+16.09%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SANOFI	+2.79%	125B
ELI LILLY AND COMPANY	+32.95%	698B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.97%	358B
MERCK & CO., INC.	+18.83%	328B
ABBVIE INC.	+3.54%	283B
ASTRAZENECA PLC	+15.91%	238B
NOVARTIS AG	+6.68%	203B
ROCHE HOLDING AG	-9.08%	198B
AMGEN INC.	+6.70%	165B

Other Pharmaceuticals

Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

SANOFI : Goldman Sachs reiterates its Buy rating

Latest news about Sanofi

Chart Sanofi

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Sanofi

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals